Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | THRB | P10828 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3300806 | 0.87 | TSHR (0.75) | TSHRSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL15068013 | 0.83 | TSHR (0.69) | TSHRSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL29483516 | 0.83 | TSHR (1.00) | TSHRSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL29483512 | 0.83 | TSHR (1.00) | TSHRSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL5307467 | 0.82 | POLB (0.73) | SMN1; SMN2ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL5736050 | 0.81 | POLB (0.58) | TSHRSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL16735251 | 0.81 | LMNA (0.62) | TSHRSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL5736053 | 0.81 | POLB (0.58) | TSHRSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL25160259 | 0.81 | SMN1; SMN2 (0.66) | TSHRSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL29483537 | 0.81 | TSHR (0.66) | TSHRSMN1; SMN2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192163-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| EP-1937632-A1 | NOVEL COMPOUNDS | Astra Zeneca AB (SE) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007039736-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192163-A1 | Novel Compounds | PAH, PC, DDC | TSHR 3069/4885SMN1; SMN2 3960/4885ALDH1A1 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.